Dominic Edelmann

Dominic Edelmann

Auto-generated profile, based on publicly available information

Dominic Edelmann

Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2018 in International Statistical Review
Verified
Journal Article
Closed access
PDF file
DEDominic Edelmann
Dominic Edelmann
Konstantinos FokianosKonstantinos Fokianos
Konstantinos Fokianos
MPMaria Pitsillou
Maria Pitsillou

13 April 2021 in Biometrics
Verified
Journal Article
Open access
PDF file
DEDominic Edelmann
Dominic Edelmann
TWThomas Welchowski
Thomas Welchowski
ABAxel Benner
Axel Benner
Distance covariance is a powerful new dependence measure that was recently introduced by Székely et al. and Székely and Rizzo. In this work, the concept of distance covariance is extended to measuring dependence between a covariate vector and a right‐censored survival endpoint by establishing an estimator based on an inverse‐probability‐of‐censoring weighted U‐statistic. The consistency of the novel estimator is derived. In a large simulation study, it is shown that induced distance covariance permutation tests show a good performance in detecting various complex associations. Applying the distance covariance permutation tests on a gene expression dataset from breast cancer patients outlines its potential for biostatistical practice.

28 April 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
DWDurgesh Wankhede
Durgesh Wankhede
NHNiels Halama
Niels Halama
MKMatthias Kloor
Matthias Kloor
DEDominic Edelmann
Dominic Edelmann
HBHermann Brenner
Hermann Brenner
MHMichael Hoffmeister
Michael Hoffmeister
Purpose: The Immunoscore predicts colorectal cancer prognosis but faces adoption barriers because of complex software and reimbursement issues. This study used open-source methods to explore a simplified prognostic model in nonmetastatic colorectal cancer by focusing on single T-cell markers. Experimental Design: A multicentric prospective cohort study in patients with nonmetastatic colorectal cancer assessed CD3+ and CD8+ tumor-infiltrating lymphocytes (TIL) in the invasive margin (IM) and tumor core (TC) using QuPath. An immune cell score (ICS), based on TIL densities (CD3-IM, CD8-IM, CD3-TC, and CD8-TC), was calculated similarly to the Immunoscore. A split sample approach (70:30) estimated adjusted HRs for cancer-specific survival in training and validation sets. Classification and regression tree analysis identified the most prognostic TIL, and its model was compared with an ICS model for performance (Brier score) and discrimination (concordance probability estimate). Results: Over a median follow-up of 9.0 years, 203 colorectal cancer–specific deaths occurred among 1,260 patients. Classification and regression tree–selected CD8-IM was the most prognostic TIL at a cutoff of 231 cells/mm2. Patients with high CD8-IM had better cancer-specific survival than low CD8-IM in both training (HR 0.58, 95% confidence interval, 0.40–0.84) and validation sets (HR 0.35, 95% confidence interval, 0.21–0.60). Brier scores of CD8-IM and ICS survival models were comparable in both training and validation cohorts, whereas the survival discrimination of CD8-IM slightly outperformed the ICS in the validation set (concordance probability estimate: CD8-IM: 0.748; ICS: 0.730). Conclusions: CD8-IM alone provided prognostic information comparable with the ICS. Simplified, cost-effective TIL assessments could improve clinical translation and guide adjuvant therapy in early-stage colorectal cancer.

6 February 2025 in Blood Cancer Discovery
Verified
Journal Article
Closed access
NLNora Liebers
Nora Liebers
ABAriane Boumendil
Ariane Boumendil
HFHervé Finel
Hervé Finel
DEDominic Edelmann
Dominic Edelmann
GKGuido Kobbe
Guido Kobbe
SDSascha Dietrich
Sascha Dietrich
Brexucabtagene autoleucel (brexu-cel) and allogeneic hematopoietic cell transplantation (alloHCT) are effective treatments for relapsed and refractory mantle cell lymphoma (r/r MCL), but the optimal choice remains unclear. We conducted an analysis of 64 patients aged ≥50 years with r/r MCL treated with brexu-cel in the ZUMA-2 study, matching them 1:1 by propensity score to 64 (of 272) patients with r/r MCL who underwent alloHCT using data from the European Society for Blood and Marrow Transplantation registry. The median follow-up time was 36.5 months for the brexu-cel cohort and 34.1 months for the matched alloHCT cohort. Patients who received brexu-cel had a significantly higher overall survival [(OS) 81.3% vs. 59.2%; HR, 0.39; P = 0.004] and lower nonrelapse mortality (3.6% vs. 21.2%; P = 0.015) 1 year after treatment. Chronic GVHD occurred within the first year in 26.9% of patients who underwent alloHCT. However, long-term progression-free survival (PFS) and OS remain comparable. Despite the limitations of this nonrandomized study, the findings indicate a superior safety profile for brexu-cel in r/r MCL. Significance: Patients aged ≥50 years with r/r MCL had superior OS and lower nonrelapse mortality 1 year after receiving brexu-cel compared with alloHCT. However, the long-term PFS and OS are similar for both treatments. Individual risk–benefit evaluation is essential to guide optimal treatment decisions.

17 February 2024 in Biometrical Journal
Verified
Journal Article
Closed access
ABAnne‐Laure Boulesteix
Anne‐Laure Boulesteix
MBMark Baillie
Mark Baillie
DEDominic Edelmann
Dominic Edelmann
LHLeonhard Held
Leonhard Held
TMTim P. Morris
Tim P. Morris
WSWilli Sauerbrei
Willi Sauerbrei

25 September 2019 in Biometrical Journal
Verified
Journal Article
Closed access
PDF file
DEDominic Edelmann
Dominic Edelmann
CHChristina Habermehl
Christina Habermehl
RSRichard F. Schlenk
Richard F. Schlenk
ABAxel Benner
Axel Benner